research

The Public Health Impact of Antiviral Therapy for Chronic Hepatitis B

Authors
Publication date
7 June 2011
Publisher
Part of the research in this thesis was financially supported by the VIRGIL EU Grant (LSHM-CT-2004-503359), LiverDoc, and EASL Sheila Sherlock fellowship. Financial support for the publication of this thesis was given by Erasmus University Rotterdam, the Department of Public Health, Erasmus MC University Medical Center, and LiverDoc.

Abstract

__Abstract__ Of the approximately 2 billion people who have been infected worldwide with the hepatitis B virus (HBV), more than 350 million are chronic carriers. HBV infection accounts for 600,000-1,200,000 deaths each year. Chronic viral hepatitis B is a major global public health problem, an important cause of morbidity and mortality from sequelae, which include chronic hepatitis, cirrhosis, and primary liver cancer. Because the course of the disease can go without clinical symptoms for a long time it is a ‘silent’ disease, and the contribution of chronic hepatitis B to global morbidity and mortality is generally underestimated

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Erasmus University Digital Repository

    redirect
    oaioai:repub.eur.nl:51635
    Last time updated on 04/08/2016